IQVIA Holdings Inc at Citigroup Inc Unplugged Medtech and Life Sciences Access Day Transcript
(technical difficulty)
thinking about both the R&DS piece and the TAS piece and then we can kind of dive in from there.
Questions & Answers
Sure. Well, you know that the TAS business went through a period of softening revenue last year. And Q4, I think, was our softest quarter of all. What we're looking for in the TAS business as we go into 2024 -- through 2024, it's kind of almost a mirror image in terms of growth from what we saw in 2023, which is to say 2023 started out strong and the growth rate trailed off as we saw pharma clients cut back on discretionary spending.
We see demand coming back, but gradually towards the back half of the year. So you had the downward trend last year in growth, and we expect the revenue to bounce back growth as we go through the year. And you might ask what gives us confidence in that and really -- and we get that question frequently, it's hard to call
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
